198 related articles for article (PubMed ID: 16269991)
21. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
Hackam DG; Khan NA; Hemmelgarn BR; Rabkin SW; Touyz RM; Campbell NR; Padwal R; Campbell TS; Lindsay MP; Hill MD; Quinn RR; Mahon JL; Herman RJ; Schiffrin EL; Ruzicka M; Larochelle P; Feldman RD; Lebel M; Poirier L; Arnold JM; Moe GW; Howlett JG; Trudeau L; Bacon SL; Petrella RJ; Milot A; Stone JA; Drouin D; Boulanger JM; Sharma M; Hamet P; Fodor G; Dresser GK; Carruthers SG; Pylypchuk G; Burgess ED; Burns KD; Vallée M; Prasad GV; Gilbert RE; Leiter LA; Jones C; Ogilvie RI; Woo V; McFarlane PA; Hegele RA; Tobe SW;
Can J Cardiol; 2010 May; 26(5):249-58. PubMed ID: 20485689
[TBL] [Abstract][Full Text] [Related]
22. Multifactorial control and treatment intensity of type-2 diabetes in primary care settings in Catalonia.
Mengual L; Roura P; Serra M; Montasell M; Prieto G; Bonet S
Cardiovasc Diabetol; 2010 Mar; 9():14. PubMed ID: 20350315
[TBL] [Abstract][Full Text] [Related]
23. Glycaemic and blood pressure controls achieved in a cohort of 318 patients with type 2 diabetes.
Buysschaert M; Hermans MP
Acta Clin Belg; 1999 Dec; 54(6):328-33. PubMed ID: 10686705
[TBL] [Abstract][Full Text] [Related]
24. [Certain beginning of insulin therapy: yes, we can, but...].
Rohrer A
Praxis (Bern 1994); 2009 Mar; 98(6):301. PubMed ID: 19338117
[No Abstract] [Full Text] [Related]
25. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
Boucek P
Vnitr Lek; 2006 Sep; 52(9):791-6. PubMed ID: 17091602
[TBL] [Abstract][Full Text] [Related]
26. [Optimised glycaemic control and dose titration with insulin glargine (Lantus) by general practitioners in Switzerland: results of the OPTI-LAN Postmarketing Study].
Spirk D; Lareida J; Scheidegger K; Diem P
Praxis (Bern 1994); 2009 Mar; 98(6):315-20. PubMed ID: 19291638
[TBL] [Abstract][Full Text] [Related]
27. [Hypertension in patients with diabetes].
Poulsen PL; Hansen KW; Gaede PH; Rossing P
Ugeskr Laeger; 2009 Jun; 171(24):2031-4. PubMed ID: 19523370
[TBL] [Abstract][Full Text] [Related]
28. Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers.
Kalaitzidis R; Bakris G
Diabetes Obes Metab; 2009 Aug; 11(8):757-69. PubMed ID: 19519867
[TBL] [Abstract][Full Text] [Related]
29. Change in cardiovascular risk factors in relation to diabetes status: the Tromso Study.
Joseph J; Svartberg J; Njølstad I; Schirmer H
Eur J Prev Cardiol; 2012 Jun; 19(3):551-7. PubMed ID: 21505026
[TBL] [Abstract][Full Text] [Related]
30. Update on Hypertension Management: treatment of hypertension in patients with type 2 diabetes mellitus.
Nilsson PM; Cifkova R; Kjeldsen SE
J Hypertens; 2006 Jan; 24(1):208-10. PubMed ID: 16331123
[No Abstract] [Full Text] [Related]
31. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS
Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
[TBL] [Abstract][Full Text] [Related]
32. Impact of a multifactorial treatment programme on clinical outcomes and cardiovascular risk estimates: a retrospective cohort study from a specialised diabetes centre in Denmark.
Safai N; Carstensen B; Vestergaard H; Ridderstråle M
BMJ Open; 2018 Mar; 8(3):e019214. PubMed ID: 29550776
[TBL] [Abstract][Full Text] [Related]
33. Health care delivery in type 2 diabetes. A survey in an Italian primary care practice.
Modesti A; Bartaloni R; Bellagamba F; Caglieri R; Cenori K; Ciampalini G; Costagli A; Galloni V; Del Papa C; Modesti L; Dell'Omo G; Pedrinelli R
Prim Care Diabetes; 2015 Feb; 9(1):9-14. PubMed ID: 24908631
[TBL] [Abstract][Full Text] [Related]
34. Difficulties in reaching therapeutic goals for hypertension and dysplipidaemia in patients with type 2 diabetes in general practice.
Knudsen ST; Mosbech TH; Hansen B; Kønig E; Johnsen PC; Kamper AL
Dan Med J; 2013 Dec; 60(12):A4740. PubMed ID: 24355449
[TBL] [Abstract][Full Text] [Related]
35. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study.
Janssen PG; Gorter KJ; Stolk RP; Rutten GE
Br J Gen Pract; 2009 Jan; 59(558):43-8. PubMed ID: 19105915
[TBL] [Abstract][Full Text] [Related]
36. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
Scheen AJ
Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
[TBL] [Abstract][Full Text] [Related]
37. Personalised treatment targets in type 2 diabetes patients: The Dutch approach.
Boels AM; Hart HE; Rutten GE; Vos RC
Prim Care Diabetes; 2017 Feb; 11(1):71-77. PubMed ID: 27633894
[TBL] [Abstract][Full Text] [Related]
38. [Compliance with the 2002 consensus document of the Spanish Society of Nephrology for the control of diabetic nephropathy in Catalonia (ECCODIAB)].
Fontseré N; Bonal J; Torres F; de las Cuevas X; Fort J
Nefrologia; 2006; 26(6):679-87. PubMed ID: 17227245
[TBL] [Abstract][Full Text] [Related]
39. [AMD Annals: a model of continuous monitoring and improvement of the quality of diabetes care].
Gruppo di studio ANNALI AMD
Epidemiol Prev; 2011; 35(1):18-26. PubMed ID: 21436491
[TBL] [Abstract][Full Text] [Related]
40. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
Turner RC; Cull CA; Frighi V; Holman RR
JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
